Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07471425) titled 'Survival Without Persistent Limiting Toxicity: Real Life Prospective Cohort of Advanced Neuroendocrine Tumor' on March 5.

Study Type: Observational [Patient Registry]

Primary Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Condition: Neuroendocrine (NE) Tumors

Intervention: Other: quality of life questionnaire, treatment side effect follow up

Recruitment Status: Not recruiting

Date of First Enrollment: June 2026

Target Sample Size: 1100

Countries of Recruitment: France

To know more, visit https://clinicaltrials.gov/study/NCT07471425

Published by HT Digital Content Services with permission from Healt...